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Abstract The functional consequences of an in vivo heterozy-
gous insertion mutation in the human facilitated glucose trans-
porter isoform 1 (GLUT1) gene were investigated. The resulting
frameshift in exon 10 changed the primary structure of the
C-terminus from 42 in native GLUT1 to 61 amino acid residues
in the mutant. Kinetic studies on a patient’s erythrocytes were
substantiated by expressing the mutant cDNA in Xenopus laevis
oocytes. Km and Vmax values were clearly decreased explaining
pathogenicity. Targeting to the plasma membrane was compa-
rable between mutant and wild-type GLUT1. Transport inhibi-
tion by cytochalasin B was more e¡ective in the mutant than in
the wild-type transporter. The substrate speci¢city of GLUT1
remained unchanged.
/ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
GLUT1 de¢ciency syndrome (GLUT1-DS) is caused by
various de novo mutations in the facilitated human glucose
transporter 1 gene (1p35^31.3) [1,2]. Mutational analysis of
GLUT1 (SLC2A1) revealed a great variety of mutation types
such as silent mutations, missense mutations, nonsense muta-
tions, deletion and insertion mutations, frameshift mutations,
or splice site mutations. Prominent clinical symptoms are per-
sistent hypoglycorrhachia, seizures, and developmental delay.
Since these mutations are heterozygous the further character-
ization of functional consequences requires a valid heterolo-
gous expression system for the a¡ected allele. Using the Xeno-
pus laevis expression system, previous kinetic analysis of the
G91D mutation in the highly conserved motif R-X-G-R-R
within the second cytoplasmic loop [3], of the T310I mutation
in transmembrane segment 8, and of the R126H mutation
within the third extracellular loop [4] not only con¢rmed these
mutations as pathogenic but also led to novel insights into
structure^function relationship of GLUT1.
Out of 22 published human GLUT1 mutations only two
nonsense mutations have been identi¢ed in exon 10 resulting
in a stop codon and truncation of the carboxy-terminus that
most likely abolishes glucose transport [2]. In parallel, patients
with GLUT1-DS carrying insertion mutations appear to be
more severely a¡ected than those with missense mutations [1].
In this study, an insertion mutation with 14 additional base
pairs in exon 10 inserted between nucleotide sequence 1540
and 1541 (numbering according to the GenBank M20681) was
identi¢ed in a 5 year old girl with GLUT1-DS. Due to the
resulting frameshift the mutant gene encodes a GLUT1 pro-
tein with a cytoplasmic C-terminal domain containing 61 in-
stead of the 42 native amino acid residues. Following the ¢rst
three N-terminal amino acid residues of the C-terminus, the
primary structure of this domain is di¡erent in sequence from
wild-type GLUT1. The functional role of the C-terminus was
previously addressed in wild-type GLUT1 by deletion muta-
genesis, point mutations, generation of chimeras between
GLUT1 and di¡erent members of the GLUT family, and
cloning of a C-terminal binding protein [5^11]. From these
studies it became obvious that the C-terminus of GLUT1 is
a functionally important structural element. Here we report
for the ¢rst time how an in vivo insertion mutation in the
human GLUT1 gene changing primary structure and length
of the C-terminus in£uences the functional characteristics of
the GLUT1 glucose transporter.
2. Materials and methods
2.1. The patient and GLUT1 genomic analyses
This 5 year old girl presented with seizures and developmental delay
in late infancy. A low glucose concentration in the cerebrospinal £uid
was suggestive of impaired GLUT1-mediated glucose transport across
the blood^brain barrier. DNA was isolated from white blood cells by
standard protocols. Genomic DNA was used as a template for poly-
merase chain reaction with speci¢c primers of the human GLUT1
gene as described previously [12]. Ampli¢cation products were visual-
ized by ethidium bromide staining on agarose gels, puri¢ed, and sub-
jected to forward (F) and reverse (R) sequencing by an automated
DNA sequencer using the following primers at exon 10: (F) ATG
ACT CCA ACC AAG TGT GTC; (R) TGT GCT CCT GAG
AGA TCC TTA. Fourteen additional base pairs (TTCAAAG-
TTCCTGA) are inserted between nucleotides 1540 and 1541 (number-
ing according to GenBank M20681, starting at position 180^182).
2.2. Zero-trans 3-O-methyl-D-glucose (3-OMG) entry into erythrocytes
The assay has been described in detail elsewhere [13]. Brie£y, blood
specimens were collected in citrate^dextrose^phosphate solution, im-
mediately put on wet ice, and processed within 10 days. All proce-
dures were performed at 4‡C. Blood samples were washed three times
in phosphate-bu¡ered saline and aliquots were incubated with increas-
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ing concentrations of 14C-labeled 3-OMG. Uptake was terminated
after 15 s, the aliquots were washed twice, lysed, bleached, and
counted in a scintillation counter (Tricarb 2300, Canberra Packard,
Germany).
2.3. Mutagenesis, in vitro transcription, and expression in X. laevis
oocytes
The above indicated insertion mutation identi¢ed in the patient was
generated in the pSP64T-GLUT1 plasmid [14^16] using the
QuickChange0 site-directed mutagenesis kit (Stratagene Europe, Am-
sterdam, The Netherlands). The correct mutagenesis was con¢rmed by
automated DNA sequence analysis. The XbaI-linearized plasmid
served as template to transcribe mutant and wild-type cRNAs using
the in vitro transcription protocol provided by Ambion (mMESSAGE
mMACHINE, Ambion, Austin, TX, USA). The amount of tran-
scribed cRNA was calculated by counting the radioactivity of incor-
porated [35S]thio-UTP. The integrity of cRNA was checked on a gel.
For each preparation, the concentrations of cRNAs were adjusted to
values of V0.3 mg/ml. Fifty nanoliters of cRNA was injected into
Xenopus oocytes which 24 h earlier had been manually isolated from
ovarian lobes. Details of collection, defolliculation, and culture of
Xenopus oocytes as well as cRNA microinjection have been described
previously [17]. According to the induced frameshift the mutant
cRNA translates into a mutant GLUT1 protein whose C-terminus
contains 61 instead of 42 amino acid residues. Except for the ¢rst
three N-terminal residues of the C-terminus the primary sequence is
di¡erent between mutant and wild-type GLUT1: wild-type: 451KVP-
E-T-K-G-R-T-F-D-E-I-A-S-G-F-R-Q-G-G-A-S-Q-S-D-K-T-P-E-E-L-
F-H-P-L-G-A-D-S-Q-V492 ; mutant: 451KVP-D-S-K-F-L-R-L-K-A-G-
P-S-M-R-S-L-P-A-S-G-R-G-E-P-A-K-V-I-R-H-P-R-S-C-S-I-P-W-G-
L-I-P-K-C-E-S-P-Q-I-T-S-P-A-C-S-Q-Q-P511.
2.4. Kinetic analysis and inhibition by cytochalasin B
Kinetic analysis was assessed under zero-trans and equilibrium ex-
change conditions. Zero-trans entry was determined using tritium-la-
beled 2-deoxy-D-glucose (2-DOG, 2 WCi/0.5 ml transport assay, 30
min uptake time period, 10^15 oocytes per assay) according to a
standard protocol [17]. 2-DOG concentrations ranged from 50 WM
(standard assay) up to 25 mM (for Michaelis^Menten kinetics). Under
equilibrium exchange condition (details in [17]) Xenopus oocytes were
equilibrated with ¢ve 3-OMG concentrations (2, 10, 30, 50, and 100
mM) for 12 h. After addition of tritium-labeled 3-OMG (5 WCi/0.5 ml
assay) accumulation of radioactivity in Xenopus oocytes was measured
at seven time points (after 2, 5, 10, 20, 30, 40, and 50 min). Accumu-
lation curves were linearized by logarithmic transformation and the
negative reciprocals of the slopes plotted against equilibrium substrate
concentrations (Hanes plot). All results were corrected for uptake in
water-injected Xenopus oocytes.
Inhibition of 2-DOG uptake by cytochalasin B was determined at
0.1, 0.5, 1.0, 5.0, and 10.0 WM inhibitor concentrations. The mean
fractional uptake rates (inhibited/non-inhibited 2-DOG uptake) were
calculated after subtraction of values from water-injected Xenopus
oocytes.
GraphPad Prism0 software was used for calculation of Km and
Vmax values.
2.5. Confocal laser scanning microscopy and Western dot blot analysis
Immunocytochemistry was performed as described previously [16]
with the following modi¢cations: the ¢rst antibody used was raised
against the whole GLUT1 protein (a kind gift from Dr. A. Schu«r-
mann, DifE, Berlin, Germany), and ¢xed oocytes were frozen before
cutting them into halves with a standard freezing microtome. In the
line scan mode, £uorescence was scanned through a depth of 10 Wm
along a line drawn from outside the plasma membrane up to 50 Wm
into the cell interior.
Plasma membrane fractions were prepared according to the proce-
dure of Keller et al. [17] with a slight modi¢cation [18]. Western dot
blots were performed as described previously [19,20] using the chem-
iluminescent detection kit for horseradish peroxidase (Applichem,
Darmstadt, Germany). The ¢rst antibody (see above) was used at
1:700 dilution; the anti-rabbit IgG (whole molecule) peroxidase-con-
jugated second antibody, developed in goat (Sigma, St. Louis, MO,
USA), was diluted 1:1000. Five, 10, 25, and 50 ng of puri¢ed GLUT1
(a kind gift from Dr. G. Lienhard, Hanover, NH, USA) served as
standards for the comparison of signal intensities.
2.6. Materials
The HPLC-puri¢ed oligonucleotides were obtained from Sigma
(Taufkirchen, Germany). The radiolabeled glucose analogs 2-[1,2-
3H]deoxy-D-glucose (concentration 37 MBq/ml, speci¢c activity
876.9 GBq/mmol) and 3-O-[methyl-3H]D-glucose (concentration 37
MBq/ml, speci¢c activity 2.3 TBq/mmol) were purchased from Perkin
Elmer Life Science (Boston, MA, USA). 2-DOG, 3-OMG, and colla-
genase type I were from Sigma. Female X. laevis frogs were from
African Xenopus Facility C.C. (Knysna, Republic of South Africa).
3. Results
The insertion of 14 additional nucleotides in exon 10 of the
human glucose transporter GLUT1 gene led to changes in the
amino acid sequence and the length of the C-terminal domain
(see Section 2). Functional consequences were suggested after
detection of a low glucose concentration in the cerebrospinal
£uid. Fig. 1 presents the results of mutant GLUT1-mediated
zero-trans entry of 3-OMG into erythrocytes. Because only
one allele is a¡ected this study represents a mixed population
of normal and mutated red blood cells. Both the half satura-
tion constant and Vmax of mutant GLUT1 were lowered to
about 30% of that of control erythrocytes. Following in vitro
mutagenesis the cDNA was subcloned into the expression
vector pSP64T, transcribed into mutant cRNA, injected into
Xenopus oocytes, and translated into the mutant GLUT1.
Fig. 2 con¢rms the results from the patient’s erythrocytes
demonstrating that the heterologously expressed mutant
GLUT1 transports 2-DOG at rates that were only 15% of
that of wild-type GLUT1. Confocal laser microscopy allowed
a rough comparison between £uorescence intensities of the
mutant and wild-type GLUT1 proteins that were recorded
from oocyte halves at the plasma membrane area and adja-
cent portions of the cytoplasm (Fig. 3A). In the line plot mode
(Fig. 3B), semi-quantitative analyses of £uorescence intensities
(details in Section 2) support the notion that the levels of
expression in the plasma membrane are comparable between
mutant and wild-type GLUT1. In the Western dot blot of
plasma membrane fractions, the signal of the mutant
GLUT1 appears marginally less intense than that of wild-
type GLUT1 (Fig. 3C). We conclude from Fig. 3 that neither
translation of the mutant cRNA nor targeting of the mutant
transporter to the plasma membrane is changed to an extent
Fig. 1. Zero-trans entry of 3-OMG into erythrocytes of the patient
(a) and two intra-assay controls (b, meansUS.E.M.) as velocity in
fmol/s/106 RBC vs. substrate concentration in mmol/l, four determi-
nations/data point.
FEBS 27852 19-11-03
P. Lange et al./FEBS Letters 555 (2003) 274^278 275
that could explain the dramatically reduced transport activity
of this mutant GLUT1.
In order to further analyze the functional characteristics of
the mutant we investigated the kinetics under two conditions,
i.e. zero-trans entry using 2-DOG and equilibrium exchange
entry using 3-OMG as glucose analogs. Representative plots
are presented in Fig. 4. In keeping with the data obtained
from erythrocytes (Fig. 1) both the apparent half-saturation
rate constant and the maximal velocity of zero-trans 2-DOG
uptake were decreased by the aberration (Fig. 4A). The ki-
netic data for wild-type GLUT1 are in agreement with pub-
lished results [21,22]. As shown in Fig. 4B, lowering of the
half-saturation rate constant by the mutation was con¢rmed
in the equilibrium exchange experiment that uses 3-OMG as a
glucose analog. Unlike 2-DOG, 3-OMG is transported but
not phosphorylated upon entry into the cell. Because of the
extremely low catalytic activity of the mutant, accumulation
of radioactivity at 100 mM 3-OMG equilibrium concentration
was not signi¢cantly di¡erent from background (missing value
in the Hanes plot). The Km of wild-type GLUT1, in line with
previously published apparent Michaelis constants [17,21,23],
con¢rms the di¡erence between values determined under equi-
librium exchange and zero-trans entry condition, respectively.
Because of the extensive scale of the equilibrium exchange
experiments di¡erent batches of oocytes from the same animal
had to be used for the kinetics of wild-type and mutant
GLUT1. Xenopus oocytes from di¡erent batches may express
slightly di¡erent levels of transporter protein in the plasma
membrane, so that values for Vmax are not mentioned for
comparison in Fig. 4B.
Mutant and wild-type GLUT1-expressing Xenopus oocytes
were subjected to transport inhibition by the exofacial inhib-
itor ethylidene glucose and the endofacial inhibitor cytocha-
lasin B. Whereas the structural changes of the C-terminus did
not a¡ect the inhibition of 2-DOG (50 Wmol/l) uptake by
ethylidene glucose (tested at the concentrations of 2, 5, 10,
20, 50, and 100 mmol/l ; data not shown), cytochalasin B
was more e¡ective in the mutant transporter compared with
control (Fig. 5). Substrate speci¢city was also tested on the
basis of 2-DOG uptake modi¢cation by L-glucose, D-mannose,
D-galactose, and D-fructose, each at 100 mM concentration.
Competition of these hexoses with 2-DOG (50 Wmol/l) for
transport was the same in mutant and wild-type GLUT1
(data not shown).
4. Discussion
An in vivo insertion mutation in the human GLUT1 gene
(1p35^31.3) led to an alteration in the C-terminus of the trans-
port protein. This changed GLUT1 toward a higher a⁄nity
Fig. 2. 2-DOG uptake rates. Uptake was determined at 50 Wmol/l
tritium-labeled 2-DOG for 30 min in water-injected Xenopus oocytes
and oocytes expressing wild-type GLUT1 or the GLUT1 C-terminal
mutant (meanUS.D.). Each assay included 30 Xenopus oocytes per
group.
Fig. 3. Confocal laser microscopy was performed in cut oocyte
halves of three randomly selected Xenopus oocytes using a ¢rst anti-
body raised against the whole GLUT1 protein (a kind gift from Dr.
A. Schu«rmann) followed by a second FITC-conjugated goat anti-
rabbit IgG antibody. Representative images (A) and line plots (B)
were obtained by scanning the £uorescence through a depth of 10
Wm along a line of about 50 Wm drawn from the outer plasma
membrane into the cell interior. The x-axis of line plots indicates
the distance in Wm, the y-axis represents the relative £uorescence in-
tensities in arbitrary units. C: For Western dot blot the same ¢rst
antibody as above was used at a 1:700 dilution. The anti-rabbit
IgG peroxidase-conjugated second antibody (Sigma) was used at a
1:1000 dilution. Five, 10, 25, and 50 ng of puri¢ed GLUT1 (a kind
gift from Dr. G. Lienhard) were applied as standards.
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and lower capacity. The functional role of the C-terminal
domain of GLUT1 has been addressed by several scienti¢c
groups with partly contradictory results. A deletion of the
entire C-terminus abolishes the catalytic activity of GLUT1
[5]. A loss of 24 residues at the C-terminal end does not
interfere with GLUT1 function while a greater deletion mark-
edly reduced transport activity [6]. Point mutations G466CE
and F467CL do not signi¢cantly alter 2-DOG uptake,
whereas the substitution of R468 with leucine leads to a slight
lowering of Km [6]. Studies with various chimeric constructs
containing parts of GLUT1 and GLUT4 underline the impor-
tance of the GLUT1 C-terminus with regard to the exocytosis
rate from the endosomal compartment to the cell surface [8].
In a GLUT1/GLUT2 chimera, the Km value was intermediate
between those of the two isoforms [10]. Results from a
GLUT1/GLUT5 chimera, however, support the notion that
the C-terminal domain does not determine isoform-speci¢c
targeting [9]. Regarding relevant isoform-speci¢c sequences
within the C-terminus, motifs like 489L-L490 or 498T-E-L-E-
Y-L-G-P505 in GLUT4 are not expressed in the mutant
GLUT1 C-terminus. The 463I-A-S-G-F-R468 sequence within
the GLUT1 C-terminal domain, shown to function as an am-
pli¢er for glucose signaling to extracellular signal-regulated
kinase [24], is missing in the mutant C-terminus.
To our knowledge a single publication refers to functional
consequences of an enlargement of the C-terminal domain of
GLUT1. The group of May and coworkers changed the C-ter-
minus by adding 31 residues from the connecting peptide of
proinsulin to the C-terminal end of GLUT1 without modify-
ing GLUT1 catalytic activity [25]. Therefore, the enlargement
per se seems not to be an important determinant for the ex-
tremely low catalytic activity of this in vivo mutation. The
highly conserved motif 501K-V-P-E-T555 at the N-terminal
end is changed in the mutant to the homologous sequence
501K-V-P-D-S555. We do not know the implication of a gluta-
mate to aspartate or threonine to serine substitution in
GLUT1 transport activity. Notably, the mutation dramati-
cally changed the balance between positively and negatively
charged amino acid residues within the C-terminus (wild-type
and mutant amino acid sequences in Section 2). Only 5% of
the side chains were negatively charged in the mutant trans-
porter compared with 17% in native GLUT1, whereas the
number of positively charged amino acids increased from
¢ve to 10 residues in the mutant. Acidic amino acids in the
C-terminus of wild-type GLUT1 may form electrostatic bonds
with basic residues in cytoplasmic loops (e.g. in the R-X-G-R-
R motif) stabilizing the helical packing arrangement. This
interaction may be partly disrupted by the in vivo mutation
leading to negative functional consequences. We have no ex-
planation concerning the more e¡ective inhibition by cytocha-
lasin B of 2-DOG uptake mediated by the mutant transporter
compared with inhibition in wild-type GLUT1.
In conclusion, our results identi¢ed the pathogenic mecha-
nism of an insertion mutation in a patient with GLUT1-DS.
The resulting frameshift leading to elongation and change in
the primary structure of the GLUT1 C-terminus impairs
GLUT1 function but not or only marginally GLUT1 expres-
sion or translocation to the cell surface. In line with previous
Fig. 4. Kinetic analysis. A: Zero-trans entry of 2-DOG at the indi-
cated concentrations was determined in Xenopus oocytes expressing
wild-type GLUT1 or the GLUT1 C-terminal mutant (Michaelis^
Menten graphs). Each value is derived from the mean of data from
15^30 oocytes (meanUS.D.) and is corrected for uptake in water-in-
jected Xenopus oocytes. B: Equilibrium exchange entry kinetics were
performed at the indicated 3-OMG equilibrium concentrations. Ac-
cumulation of [3H]3-OMG was assessed at 2, 5, 10, 20, 30, 40, and
50 min and linearized by logarithmic transformation. For each time
point, 8^10 Xenopus oocytes per group were included in the assay.
Values from water-injected oocytes were always subtracted. In the
mutant, accumulation of radioactivity at 100 mM 3-OMG equilibri-
um concentration led to negligible counts. The negative reciprocals
of the slopes were plotted against 3-OMG concentrations (Hanes
plots). Km and Vmax values were calculated using the GraphPad
Prism0 software.
Fig. 5. Inhibition by cytochalasin B (CB) of 2-DOG uptake. Xeno-
pus oocytes expressing wild-type GLUT1 or the C-terminal mutant
were incubated with CB at the indicated concentrations. Values
obtained in water-injected Xenopus oocytes were always subtracted.
Inhibition is expressed as mean fractional uptake rates (v/vo =
inhibited/non-inhibited uptake rates). Curve ¢tting was performed
with the GraphPad Prism0 software.
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observations, the C-terminus is essential for GLUT1 transport
function. Further analyses of GLUT1 mutations in patients
with GLUT1-DS will help to identify additional structure^
function relationships within the GLUT1 transport protein.
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